Exelixis (NASDAQ:EXEL) Director Mary Beckerle Sells 9,812 Shares

Exelixis, Inc. (NASDAQ:EXEL) Director Mary Beckerle sold 9,812 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $53.66, for a total value of $526,511.92. Following the completion of the transaction, the director directly owned 16,079 shares in the company, valued at $862,799.14. The trade was a 37.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Exelixis Trading Down 1.9%

Shares of EXEL opened at $50.38 on Thursday. The stock has a market cap of $12.48 billion, a P/E ratio of 15.84, a price-to-earnings-growth ratio of 1.55 and a beta of 0.44. Exelixis, Inc. has a 1 year low of $33.76 and a 1 year high of $57.57. The stock’s 50-day moving average price is $54.25 and its two-hundred day moving average price is $48.12.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.06. The company had revenue of $628.69 million during the quarter, compared to analysts’ expectations of $636.40 million. Exelixis had a return on equity of 42.17% and a net margin of 35.33%.Exelixis’s revenue was up 10.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.75 EPS. As a group, equities analysts forecast that Exelixis, Inc. will post 3.14 EPS for the current year.

Analyst Upgrades and Downgrades

EXEL has been the topic of several analyst reports. Citigroup reiterated a “market outperform” rating on shares of Exelixis in a report on Wednesday, July 22nd. Wall Street Zen cut shares of Exelixis from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Zacks Research downgraded Exelixis from a “hold” rating to a “strong sell” rating in a research note on Monday, August 3rd. UBS Group set a $55.00 price objective on Exelixis in a research note on Monday, August 3rd. Finally, TD Cowen boosted their target price on Exelixis from $51.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $49.79.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Exelixis by 81.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company’s stock worth $1,592,000 after purchasing an additional 19,407 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Exelixis by 4.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company’s stock valued at $54,153,000 after purchasing an additional 68,133 shares during the period. Focus Partners Wealth raised its stake in shares of Exelixis by 83.4% in the 1st quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company’s stock valued at $1,420,000 after purchasing an additional 17,483 shares during the period. Geneos Wealth Management Inc. lifted its holdings in shares of Exelixis by 134.3% in the first quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 944 shares in the last quarter. Finally, Sivia Capital Partners LLC lifted its holdings in shares of Exelixis by 23.8% in the second quarter. Sivia Capital Partners LLC now owns 14,362 shares of the biotechnology company’s stock valued at $633,000 after purchasing an additional 2,764 shares in the last quarter. Institutional investors own 85.27% of the company’s stock.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.